Trials / Completed
CompletedNCT04363736
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in hospitalized adult participants with moderate to severe COVID-19 pneumonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tociliuzumab | Participants will receive IV TCZ. |
Timeline
- Start date
- 2020-05-05
- Primary completion
- 2020-08-12
- Completion
- 2020-08-12
- First posted
- 2020-04-27
- Last updated
- 2022-08-31
- Results posted
- 2021-08-30
Locations
24 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04363736. Inclusion in this directory is not an endorsement.